CONCLUSION Human urinary kallikrein is effective and relatively safe in treatment of acute cerebral infarction in the vascular distribution of the internal carotid artery.
结论人尿激肽原酶治疗急性颈内动脉系统脑梗死所致的神经功能缺损，其效果及安全性良好。
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.
本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.
本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。
应用推荐